重组血栓调节蛋白治疗特发性间质性肺炎急性加重
本研究评估重组人可溶性血栓调节蛋白(rhTM)治疗特发性间质性肺炎急性加重(AE-IIP)的疗效与安全性。采用前瞻性单臂开放标签多中心队列设计,回顾性注册61例常规治疗对照,前瞻性入组39例常规治疗联合rhTM(380 U/kg/天×6天)。调整混杂后rhTM与90天死亡率降低显著相关(调整HR 0.453;95%CI 0.237-0.864;P=0.0163),不良事件发生率两组相似。
要点
- rhTM联合常规治疗与AE-IIP患者90天死亡率降低显著相关。
- rhTM组不良事件频率与对照组相似,但发生2例出血相关不良事件。
- 结论需未来随机对照试验验证。
核心结论
- rhTM治疗AE-IIP观察到安全性和有效性,但最终结论需随机对照试验。
研究设计与样本
- 前瞻性单臂开放标签多中心队列研究,回顾性注册61例常规治疗对照(2011-2013年),前瞻性入组39例常规治疗联合rhTM(2014-2016年)。
- rhTM剂量为380 U/kg/天,持续6天。
- 采用逆概率治疗加权Cox比例风险模型调整混杂因素。
主要发现
- rhTM组90天生存率为66.7%(26/39),对照组为47.5%(29/61)。
- 调整后rhTM治疗与死亡率降低显著相关(调整HR 0.453;95%CI 0.237-0.864;P=0.0163)。
- 不良事件频率rhTM组17.9%(7/39),对照组19.7%(12/61),两组相似(P=1.0)。
- rhTM组发生2例出血相关不良事件。
关键数值与推荐
- rhTM用法:380 U/kg/天,持续6天。
- 90天生存率:rhTM组66.7%(26/39),对照组47.5%(29/61)。
- 调整HR 0.453(95%CI 0.237-0.864;P=0.0163)。
- 不良事件频率:rhTM组17.9%(7/39)vs 对照组19.7%(12/61),P=1.0。
临床怎么用
- 对于AE-IIP患者,在常规治疗基础上可考虑联合rhTM,但需权衡出血风险。
- 目前证据来自非随机对照研究,临床决策应个体化并等待随机对照试验结果。
局限性
- 研究为非随机对照设计,尽管采用倾向评分加权调整,仍可能存在残余混杂。
- 样本量有限,rhTM组仅39例。
- 作者指出需要未来随机对照试验以得出最终结论。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Acute exacerbation (AE) in idiopathic pulmonary fibrosis (IPF) or other idiopathic interstitial pneumonias (IIP) is a poor prognostic event despite conventional therapy with corticosteroids and/or immunosuppressants. We aimed to evaluate the efficacy and safety of recombinant human soluble thrombomodulin (rhTM) for AE-IIP. METHODS: For this prospective single-arm open-label multicentre cohort study, we retrospectively registered 61 cases of AE-IIP treated with conventional therapy between 2011 and 2013 (control arm), and prospectively enrolled 39 cases of AE-IIP treated with conventional therapy and rhTM (380 U/kg/day for 6 days) between 2014 and 2016 (rhTM arm). To reduce potential confounding in treatment comparisons, an adjusted mortality analysis for 90-day survival was conducted with weighted Cox proportional hazards regression models using inverse probability of treatment weighting. Weights were derived from propensity scores estimated using a multivariable logistic regression analysis including potential confounders. RESULTS: The 90-day survival rates of AE-IIP patients treated with/without rhTM were 66.7% (26/39) and 47.5% (29/61), respectively. After adjusting for imbalances, rhTM therapy was significantly associated with reduced mortality (adjusted hazard ratio (HR): 0.453; 95% CI: 0.237-0.864; P = 0.0163). The frequencies of adverse events with/without rhTM were 17.9% (7/39) and 19.7% (12/61), which were similar in both arms (P = 1.0). Two bleeding-related adverse events occurred in the rhTM arm. CONCLUSION: Safety and efficacy were observed for rhTM treatment of AE-IIP. A future randomized controlled trial is required to draw final conclusions.
引用
- Arai T, Kida H, Ogata Y, et al. Recombinant thrombomodulin for acute exacerbation in idiopathic interstitial pneumonias. Respirology. 2019. PMID: 30835911. doi:10.1111/resp.13514
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。